Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

Press Releases

  • 08/31/2017

    PDA Assists Pharma Manufacturing Upgrades with Points to Consider for Aging Facilities

    Bethesda, Md., August 31, 2017 – The Parenteral Drug Association (PDA) published Points to Consider for Aging Facilities as part of an ongoing focus on manufacturing improvements. In some cases, noncompliant, aging facilities are a reason forcing companies to cease manufacturing, which may exacerbate drug shortages.
  • 07/28/2017

    Change Regulations Hinder Pharma Innovation According to PDA PAC iAM Survey

    Bethesda, Md., July 28, 2017 – The Parenteral Drug Association (PDA) today announces the results of its pharma/biopharma survey regarding the impact of national-level post-approval change regulations on company’s ability to innovate.
  • 06/13/2017

    PDA Workshop on EMA Annex1 Revision Draws Discussion of Difficult Topics

    Bethesda, Md., June 12, 2017 – The Parenteral Drug Association (PDA) today announced the successful completion of its Annex 1 Revision Workshop, which afforded industry a final preview before the revised guidance for aseptic processing GMPs is issued as early as the end of the month.
  • 05/25/2017

    The Parenteral Drug Association Connecting Drug Manufacturers, Glass Suppliers to make Manufacturing Great

    Bethesda, Md., May 25, 2017 – The Parenteral Drug Association (PDA) is proud to announce a significant initiative to bring together executives, including CEOs and executive vice presidents, from biologic and pharmaceutical manufacturers with glass container and elastomeric closure suppliers to prepare industry for the complex products and manufacturing processes of the future.
  • 05/16/2017

    PDA QRM Technical Report and Workshop Advancing Manufacturing Science

    Bethesda, Md., May 15, 2017 – The Parenteral Drug Association (PDA) today announced the publication of Technical Report No. 54-5: Quality Risk Management for the Design, Qualification, and Operation of Manufacturing Systems,which provides a practical guide on how to manage quality risks throughout the manu­facturing system lifecycle. Technical Report 54-5 includes two case studies illustrative of the concepts developed in the main body of the document. In June, PDA is sponsoring the 2017 Quality Risk Management for Manufacturing Systems Workshop,which will cover the concepts elucidated in Technical 54-5, at the Hyatt Centric Chicago Magnificent Mile, Chicago, Ill., June 19-20.
  • 05/09/2017

    Several PDA Leaders Recognized as Top “Industry Influencers” in Drug Development and Manufacture in 2017

    Bethesda, Md., May 8, 2017 – The Parenteral Drug Association, Inc. (PDA) is pleased to announce that President & CEO Richard Johnson, volunteer Chair Martin Van Trieste, and past chairs Maik Jornitz and James Agalloco have been recognized by The Medicine Maker among the "top 100 individuals involved in bettering the pharma industry and bringing life-changing medicines to market."
  • 05/04/2017

    PDA Announces Regulatory Speakers at Revision of Annex 1 Workshop in Berlin

    Bethesda, Md., May 3, 2017 – The Parenteral Drug Association (PDA) today released the names of confirmed health authority speakers at its 2017 Revision of Annex 1 Workshop, at the Hilton Berlin, June 12, 2017, which precedes the 2nd PDA Europe Annual Meeting: Global Healthcare of the Present & Future, June 13-14.
  • 04/03/2017

    PDA Becomes an ANSI Accredited Standards Developer

    Anaheim, Ca. April 3, 2017 – The Parenteral Drug Association (PDA) today announced that it has been approved by the Executive Standards Council (ExSC) of the American National Standards Institute (ANSI) as an Accredited Standard Developer (ASD). The announcement was made during the opening session of PDA’s Annual Meeting at the Anaheim Marriott.
  • 03/02/2017

    PDA PAC iAM Task Force Publishes Two Papers Journal of Pharmaceutical Science and Technology

    Bethesda, Md., March 2, 2017 – The Parenteral Drug Association (PDA) today announced the availability of two “PDA Papers” authored by the Post-Approval Changes for Innovation in Availability of Medicines (PAC iAM) Task Force in the “Accepted Articles” section of the PDA Journal of Pharmaceutical Science and Technology (PDA Journal).
  • 02/28/2017

    PDA Adds ISO Class 8 Cleanroom as Part of Training and Research Institute Enlargement Expansion includes additional classrooms, larger gowning room, and a new student lounge

    Bethesda, Md., February 27, 2017 – The Parenteral Drug Association (PDA) today announced the completion of a six-month enlargement of its Training and Research Institute (TRI) in Bethesda. The expansion permits PDA Education to increase its capacity for hands-on aseptic processing and lecture-based training at TRI.
  • 02/08/2017

    PDA Confirms Five FDA Speakers at the 2017 Quality Metrics & Culture Conference

    Bethesda, Md., February 8, 2017 – The Parenteral Drug Association (PDA) today announced that five U.S. FDA experts are confirmed speakers at the 2017 PDA Pharmaceutical Quality Metrics and Culture Conference at the Bethesda North Marriott & Conference Center, Feb. 21-22.